La cadena de opciones muestra datos clave de las opciones de acciones de TNF Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para TNF Pharmaceuticals..

TNF Pharmaceuticals (NASDAQ:TNFA) Bolsa, Cadena de Opciones

TNF Pharmaceuticals

MyMD Pharmaceuticals

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.

WIIM

ProMIS Neurosciences shares are trading higher HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a price target of $4.

No gainer in today's Pre-market session. 
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.4100</td>
<td align="right">-0.400</td>
<td align="right">-0.50</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.6660</td>
<td align="right">-0.524</td>
<td align="right">-0.39</td>
<td>15.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">254.9200</td>
<td align="right">-0.930</td>
<td align="right">-0.37</td>
<td>22.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">149.7782</td>
<td align="right">-0.422</td>
<td align="right">-0.29</td>
<td>697</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">52.0500</td>
<td align="right">-0.110</td>
<td align="right">-0.22</td>
<td>298.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">88.9700</td>
<td align="right">-0.160</td>
<td align="right">-0.18</td>
<td>88.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">82.3900</td>
<td align="right">-0.060</td>
<td align="right">-0.08</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">105.9300</td>
<td align="right">-0.080</td>
<td align="right">-0.08</td>
<td>842</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">221.3100</td>
<td align="right">-0.120</td>
<td align="right">-0.06</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For July 14, 2025

JMP Securities analyst Brian McKenna maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Market Outperform and raises the price target from $185 to $195.

News

Price Target

Analyst Ratings

ARES

JMP Securities Maintains Market Outperform on Ares Management, Raises Price Target to $195

Watts Water Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) today announced that Ryan Lada has been appointed Chief Financial Officer effective July 28, 2025. Mr. Lada succeeds current Chief Financial Officer Shashank Patel, who previously announced his intent to retire in October 2024.
 &nbsp;

Management

Watts Water Technologies Appoints Ryan Lada Succeeding Shashank Patel As CFO, Effective July 28, 2025

<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14091029/AI_image_MS_Designer_DeFi_TradFi_bridge_02-1024x585.jpeg" alt="" class="wp-image-15741" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14091029/AI_image_MS_Designer_DeFi_TradFi_bridge_02-1024x585.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14091029/AI_image_MS_Designer_DeFi_TradFi_bridge_02-300x172.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14091029/AI_image_MS_Designer_DeFi_TradFi_bridge_02-768x439.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14091029/AI_image_MS_Designer_DeFi_TradFi_bridge_02.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
A new unified cloud platform promises to accelerate crypto's app era, dramatically expanding what's possible in decentralized finance (DeFi).
Eigencloud — backed by a $70 investment from Andreesen Horowitz — offers something novel: an Ethereum development infrastructure that makes ‘virtually anything verifiable on-chain.' Just as AWS once unleashed SaaS and the cloud economy, Eigencloud's arrival potentially unlocks a huge array of DeFi use cases.
By blending Web2 flexibility with Web3 verifiability, the aim is to help dApp developers get over their trust issues. The question is: can it really work and scale?
<h1 class="wp-block-heading">The final bridge between FinTech and&nbsp;DeFi?</h1>
Eigen Labs CEO Sreeram Kannan said EigenCloud "will enable the next generation of disruptive, mass-market crypto apps, closing the gap between what developers want to build on-chain and what blockchains allow them to build."
By expanding the programmability of crypto, Kannan says Eigencloud could make "virtually anything" verifiable on-chain, opening the door to dApp opportunities like fully on-chain gaming, on-chain insurance, more powerful prediction markets, and even "verifiable" AI.
In an echo of how AWS changed the startup economy, EigenCloud aims to spur dApp innovation by allowing developers to access technical services without staking loads of native tokens.
It slashes startup costs and gives new projects the flexibility to use mainstream assets like Ethereum (ETH) and reduce dependence on token issuance.
It seems very similar to the period in the mid-2000s&nbsp;when AWS launched, and server costs began to fall.
<h1 class="wp-block-heading">Trust is the missing&nbsp;link</h1>
EigenCloud's unique selling proposition is based on the&nbsp;<a href="https://www.researchgate.net/publication/373487888_State_of_the_Art_Report_Verified_Computation" rel="noreferrer noopener" target="_blank">verifiable compute</a>&nbsp;thesis, where heavier computing operations can be outsourced from one machine to another for efficiency. It adds mechanisms to ensure trust, for example, verifying that the outsourced machine sends back a complete and error-free result.
To that end, EigenCloud embeds two new primitives, EigenCompute and EigenVerify.
EigenCompute gives developers a container-based environment that removes some of the operational complexity from setting up the external operators. Similar to serverless platforms like AWS Lambda, developers can use it to create custom logic with fewer steps. EigenCloud handles the trust coordination and execution.
EigenVerify introduces a new verification-as-a-service model. Developers can use its pre-built verification modules and write them directly into new dApps, removing the need to create new trust frameworks from scratch. This has the potential to shorten development timelines and accelerate time-to-market.
<h1 class="wp-block-heading">An AWS Model for the Decentralized Web</h1>
The thing that sets EigenCloud apart is its ability to offer verifiability for off-chain processes, mimicking what L1 chains can do on-chain. This gives developers more freedom to build Ethereum applications that use external data or other off-chain resources without compromising integrity.
Key to all of this are the platform's verifiable service composition and cross-chain support features. These enable Ethereum dApps to communicate with actively validated services (AVS), using APIs for things like payment or user authentication. EigenCloud says all three can operate across any L1 or L2, extending the capabilities of new applications.
Once again, the AWS cloud infrastructure analogy seems apropos. SaaS developers leverage AWS' pre-built solutions for storage, compute, and identity management, which can be easily added to new cloud applications. EigenCloud is aiming to bring the same kind of modular development tools to the blockchain.
AVSs, which undergo continuous validation to ensure their security, integrity, and efficiency, are crucial to verifiability.
EigenCloud allows them to be slotted into new dApps like Lego blocks. Rather than requiring each AVS to have its own custom interface, they can simply plug into a shared framework.
Standardization smoothes the way for developers and brings more reusable components into play.
<h1 class="wp-block-heading">The Take&nbsp;Away</h1>
When AWS launched in 2022, it was an interesting side project. Amazon engineers were complaining about the inordinate amount of time they were spending building and maintaining e-commerce infrastructure. ‘The cloud' hadn't even been coined as an industry term.
Today, AWS is the bedrock of the digital economy and a $107 billion cash cow for one of the world's biggest companies. Could Eigencloud follow a similar path?
Featured Image credit: Author

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Opinion

Tech

General

Crypto's Cloud Moment Is Here

Wells Fargo analyst Michael Sison maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Equal-Weight and raises the price target from $76 to $90.

Wells Fargo Maintains Equal-Weight on Westlake, Raises Price Target to $90

CLGN

CollPlant Biotechnologies shares are trading higher after the company announced it has appointed Bowman Badley as the new head of its North American commercial operations for collagen biomaterials.

JMP Securities analyst Matthew Carletti initiates coverage on Slide Insurance Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDE#NASDAQ">SLDE</a>) with a Market Outperform rating and announces Price Target of $25.

Initiation

SLDE

JMP Securities Initiates Coverage On Slide Insurance Holdings with Market Outperform Rating, Announces Price Target of $25

Wells Fargo analyst Michael Sison maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Overweight and raises the price target from $70 to $75.

Wells Fargo Maintains Overweight on LyondellBasell Industries, Raises Price Target to $75

Trading Ideas

BMNR

BitMine Immersion Technologies Shares Resume Trade

Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) today announced that it has received orders for its high-energy non-intrusive cargo and vehicle inspection systems valued at approximately $17 million USD from international customers. The systems will be placed at strategic locations securing sea and land ports.

Contracts

VREX

Varex Imaging Secures $17M Orders For High-Energy Cargo And Vehicle Inspection Systems From International Customers

Wells Fargo analyst Michael Sison maintains Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) with a Equal-Weight and raises the price target from $38 to $48.

NGVT

Wells Fargo Maintains Equal-Weight on Ingevity, Raises Price Target to $48

JMP Securities analyst Jordan Bender initiates coverage on Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Market Outperform rating and announces Price Target of $15.

SGHC

JMP Securities Initiates Coverage On Super Group (SGHC) with Market Outperform Rating, Announces Price Target of $15

RANI

Rani Therapeutics shares are trading higher after the company announced it has unveiled preclinical data at ENDO 2025 for the RaniPill capsule.

Grayscale Investments&#xAE; today announced that it has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the "SEC"). The number of shares to be registered and the price range for the proposed registration have not yet been determined. The registration is expected to take place after the SEC completes its review process, subject to market and other conditions.

Offerings

GBTC

Grayscale Investments Files Confidential Draft Registration Statement With SEC For Potential Public Offering; No Size Or Amount Disclosed

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension.
The trial included patients who were treated with two different antihypertensive medications and patients with resistant hypertension being treated with three or more different antihypertensive medications, one of which is a diuretic.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html" rel="noreferrer noopener">trial</a> showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" rel="noreferrer noopener">AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment</a>
The trial also met all secondary endpoints. Patients with uncontrolled or treatment-resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated and had a favourable safety profile.
There are 1.3 billion people worldwide living with hypertension. When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure, and kidney disease. In the U.S., approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control.
The data will be shared with regulatory authorities worldwide and presented in a late‑breaking Hot Line session at the European Society of Cardiology (ESC) Congress&nbsp;in August 2025.
AstraZeneca acquired baxdrostat by purchasing CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash ($0.5 billion) is payable to former CinCor shareholders upon submitting a new drug application in the U.S. or Europe.
In related news, Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) recently received priority review from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA) for <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46230333/mercks-hypertension-drug-on-fda-fast-track-for-label-expansion" rel="noreferrer noopener">Winrevair (sotatercept-csrk)</a>.
This application aims to update the U.S. product label based on compelling data from the Phase 3 ZENITH trial. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025.
In 2024, Winrevair was approved for adults with pulmonary arterial hypertension (PAH, Group 1 PH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.
Price Action: AZN stock is trading higher by 0.60% to $71.57 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46387027/alibaba-bleeds-billions-as-delivery-price-war-erases-100-billion-in-market-value" target="_blank" rel="noreferrer noopener">Alibaba Bleeds Billions As Delivery Price War Erases $100 Billion In Market Value</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Biotech

Large Cap

Health Care

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

Wells Fargo analyst Michael Sison maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $81 to $90.

Wells Fargo Maintains Overweight on DuPont de Nemours, Raises Price Target to $90

NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with <a href="https://www.globenewswire.com/Tracker?data=YXbNBFfgAsVdTtDothm2jIdMMfwCu1P_YBsPbn6Bx9rfv6SsL5ig3EsHn-tNOGOhTdcI8OJr6ag6Y0wCCAbhRH2JnfMUaAyAe3cdjIGmp0g=">STADA Arzneimittel AG</a> ("STADA"), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks.
As part of the agreement, STADA will advance $1 million to NEXGEL in non-dilutive capital to support product launches and marketing efforts.

NXGL

NEXGEL Expands Partnership With STADA To Launch New Digestive And Skin Care Products, Receives $1M Non-Dilutive Funding

Offering to be led by Heights Capital Management, Inc., and will consist of ordinary shares sold at $4.00 per share, accompanied by warrants with an exercise price of $4.60.

LAES

SEALSQ Prices $60M Registered Direct Offering Of 15M Shares And Accompanying Warrants At Combined Price Of $4.00/Ordinary Share And Accompanying Warrants

Susquehanna analyst Mehdi Hosseini maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Positive and raises the price target from $255 to $265.

Susquehanna Maintains Positive on Taiwan Semiconductor, Raises Price Target to $265

Press Releases

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

Comments

TNF Pharmaceuticals

TNF Pharmaceuticals (TNFA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL